5/27
07:44 am
npce
NeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 47% stake, while 24% is held by institutions [Yahoo! Finance]
Medium
Report
NeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 47% stake, while 24% is held by institutions [Yahoo! Finance]
5/14
04:05 pm
npce
NeuroPace to Participate in Two Healthcare Conferences in May
Medium
Report
NeuroPace to Participate in Two Healthcare Conferences in May
5/13
10:56 am
npce
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
11:09 am
npce
NeuroPace, Inc. (NASDAQ: NPCE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
High
Report
NeuroPace, Inc. (NASDAQ: NPCE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
5/8
04:23 pm
npce
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/8
04:05 pm
npce
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
High
Report
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
4/17
04:19 pm
npce
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]
Low
Report
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]
4/17
04:05 pm
npce
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
Low
Report
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
3/27
04:05 pm
npce
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
Medium
Report
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
3/21
02:43 pm
npce
Revamp Medical Announces Appointment of Mike Favet as CEO [Yahoo! Finance]
Neutral
Report
Revamp Medical Announces Appointment of Mike Favet as CEO [Yahoo! Finance]
3/14
08:30 am
npce
NeuroPace, Inc. (NASDAQ: NPCE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $16.00.
Medium
Report
NeuroPace, Inc. (NASDAQ: NPCE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $16.00.
3/11
04:40 am
npce
Neuroprosthetics Market to Reach $26.12 Billion by 2030, Says Coherent Market Insights [Yahoo! Finance]
Medium
Report
Neuroprosthetics Market to Reach $26.12 Billion by 2030, Says Coherent Market Insights [Yahoo! Finance]
3/7
12:03 pm
npce
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
05:26 am
npce
NeuroPace Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
Low
Report
NeuroPace Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
3/6
12:35 pm
npce
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Morgan Stanley from $9.00 to $13.00. They now have an "equal weight" rating on the stock.
Medium
Report
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Morgan Stanley from $9.00 to $13.00. They now have an "equal weight" rating on the stock.
3/6
12:35 pm
npce
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Cantor Fitzgerald from $16.00 to $18.00. They now have an "overweight" rating on the stock.
Medium
Report
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Cantor Fitzgerald from $16.00 to $18.00. They now have an "overweight" rating on the stock.
3/5
04:10 pm
npce
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million [Yahoo! Finance]
Low
Report
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million [Yahoo! Finance]
3/5
04:05 pm
npce
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
High
Report
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million